Gadoteridol
Chemical compound
- V08CA04 (WHO)
- CA: ℞-only[2]
- US: WARNING[1]Rx-only
- gadolinium(+3) cation; 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
- 120066-54-8
Y
- 60714
- DB00597
Y
- 54719
Y
- 0199MV609F
- D01137
Y
- CHEBI:31643
Y
- ChEMBL1200593
N
- DTXSID2048662
- Interactive image
- [Gd+3].[O-]C(=O)CN1CCN(CCN(CCN(CC(O)C)CC1)CC([O-])=O)CC([O-])=O
InChI
- InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3
Y
- Key:DPNNNPAKRZOSMO-UHFFFAOYSA-K
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.[3] Gadoteridol was first approved for use in the United States in 1992.[4]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Prohance Product information". Health Canada. 30 July 1998. Retrieved 19 April 2024.
- ^ Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. Retrieved 17 May 2023.
- ^ Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN (April 2011). "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology. 259 (1): 109–16. doi:10.1148/radiol.10100906. PMID 21248237.
Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.
- v
- t
- e
Iodinated, Water soluble |
| ||||||
---|---|---|---|---|---|---|---|
Iodinated, Water insoluble |
| ||||||
Non-iodinated |
Paramagnetic | |
---|---|
Superparamagnetic |
|
Other |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This article about magnetic resonance imaging is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e